Skip to main content

Sarepta Therapeutics, Inc. (SRPT)

NASDAQ: SRPT · Delayed Price · USD
80.15
-0.77 (-0.95%)
Pre-market:Oct 22, 2021 7:53 AM EDT
80.92
1.04 (1.30%)
At close: Oct 21, 4:00 PM
Market Cap6.95B
Revenue (ttm)600.08M
Net Income (ttm)-634.47M
Shares Out79.75M
EPS (ttm)-8.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume532,323
Open79.88
Previous Close79.88
Day's Range79.88 - 81.57
52-Week Range65.30 - 181.83
Beta1.42
AnalystsBuy
Price Target122.12 (+50.9%)
Est. Earnings DateNov 4, 2021

About SRPT

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping....

IndustryBiotechnology
IPO DateJun 3, 1997
CEODouglas Ingram
Employees866
Stock ExchangeNASDAQ
Ticker SymbolSRPT
Full Company Profile

Financial Performance

In 2020, SRPT's revenue was $540.10 million, an increase of 41.82% compared to the previous year's $380.83 million. Losses were -$554.13 million, -22.51% less than in 2019.

Financial Statements

Analyst Forecast

According to 23 analysts, the average rating for SRPT stock is "Buy." The 12-month stock price forecast is 122.12, which is an increase of 50.91% from the latest price.

Price Target
$122.12
(50.91% upside)
Analyst Consensus: Buy

News

Is This Beaten Down Biotech a Bad News Buy?

It has lagged the market over the last five years but with a promising gene therapy, is Sarepta worth another look?

Other symbols:NVSUTHRVRTX
2 days ago - The Motley Fool

What's Next For Sarepta Stock After A 12% Fall?

The stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, plunged 12% yesterda...

3 days ago - Forbes

Why Sarepta Therapeutics Fell 14.7% This Week

Investors were unimpressed by the company's clinical and financial news.

1 week ago - The Motley Fool

4 Biotechs to Watch Amid Rising Prominence of Gene Therapies

Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, that have the potential to gain from their promising gene therapy pipeline candidates.

Other symbols:BEAMCRSPEDIT
1 week ago - Zacks Investment Research

Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has priced an underwritt...

1 week ago - GlobeNewsWire

Why Sarepta Therapeutics Tumbled Today

Investors weren't wowed by a company update, or by news of a fresh stock issue.

1 week ago - The Motley Fool

Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quar-ter Ended September 30, 2021

CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced preliminary financial results fo...

1 week ago - GlobeNewsWire

Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock

CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (Nasdaq:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it is offering to sell, sub...

1 week ago - GlobeNewsWire

Sarepta's Duchenne Gene Therapy Shows Sustained Functional Improvements

Sarepta Therapeutics Inc (NASDAQ: SRPT) shared new analyses and functional data from its SRP-9001 development program and the details of Study SRP-9001-301 (EMBARK) Phase 3 trial of SRP-9001 for Duchenn...

1 week ago - Benzinga

Sarepta Therapeutics' SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne

CAMBRIDGE, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared new analyses and functional data fr...

1 week ago - GlobeNewsWire

Here's where investors can find opportunity in pharma

Alethia Young of Cantor Fitzgerald joins Closing Bell with her stock picks from the pharmaceutical sector that have great growth opportunity for investors.

Other symbols:GILDTGTX
1 week ago - CNBC Television

Sarepta, Codiak Nix Exosome Therapy Development Pact

Sarepta Therapeutics Inc (NASDAQ: SRPT) notified Codiak BioSciences Inc (NASDAQ: CDAK) that it would terminate the two-year Research License and Option agreement early.  The termination will be effectiv...

1 week ago - Benzinga

Sarepta (SRPT) Begins Pivotal Study on DMD Gene Therapy

Sarepta (SRPT) is developing its lead gene therapy candidate, SRP-9001, as a potential one-time treatment for DMD.

2 weeks ago - Zacks Investment Research

Sarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio

CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today celebrated the grand opening of the Geneti...

2 weeks ago - GlobeNewsWire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2021 tha...

3 weeks ago - GlobeNewsWire

Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Am...

-  Company Anticipates Part B of MOMENTUM to Serve as Pivotal Study for SRP-5051 and to Seek Accelerated Approval if Successful -  Ambulatory and Non-Ambulatory Patients Between the Ages of 7 to 21 Will...

3 weeks ago - GlobeNewsWire

5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal

The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others

Other symbols:MGTXQURESLDBVYGR
1 month ago - Zacks Investment Research

Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Co...

CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the World Muscle Society 2021 V...

1 month ago - GlobeNewsWire

Sarepta Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will par...

1 month ago - GlobeNewsWire

How Does Sarepta's Stock Performance In The Current Crisis Compare With That In 2008?

We believe that ​Sarepta Therapeutics stock, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, is a good buying...

1 month ago - Forbes

Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on August 31, 2021 that we...

1 month ago - GlobeNewsWire

Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021?

One particular group of stocks is overrepresented among the exchange's biggest losers this year. That's an important detail.

Other symbols:ABCLACADFOLDTGTX
2 months ago - The Motley Fool

Sarepta (SRPT) Q2 Earnings Beat, 2021 Sales View Raised

Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in Q2. The company also raises revenues guidance for the year.

2 months ago - Zacks Investment Research

Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 0.97% and 11.29%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research